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Abstract Acute lymphoblastic leukemia of T cell lineage (T-
ALL) is an aggressive malignant disease which accounts for
15 % of childhood ALL. T(11;14) is the more frequent chro-
mosomal abnormality in childhood T-ALL, but its prognostic
value remained controversial. Our aim was to analyze the
outcome of childhood T-ALL with t(11;14) to know if the
presence of this translocation is associated with a poor prog-
nosis. We conducted a retrospective study from a series of 20
patients with t(11;14), treated in two consecutive trials from
the European Organization for Research and Treatment of
Cancer Children Leukemia Group over a 19-year period from
1989 to 2008. There were no significant differences between
the 2 consecutive groups of patients with t(11;14) regarding
the clinical and biological features at diagnosis. Among 19
patients who reached complete remission, 9 patients relapsed.
We noticed 7 deaths all relapse- or failure-related. In the
58881 study, a presence of t(11;14) was associated with a poor
outcome with an event-free survival at 5 years at 22.2 % ver-
sus 65.1 % for the non-t(11;14) T-ALL (p=0.0004). In the
more recent protocol, the outcome of T-ALL with t(11;14)
reached that of non-t(11;14) T-ALL with an event-free surviv-
al at 5 years at 65.5 versus 74.9 % (p=0.93). The presence of
t(11;14) appeared as a poor prognostic feature in the 58881
trial whereas this abnormality no longer affected the outcome
in the 58951 study. This difference is probably explained by
the more intensive chemotherapy in the latest trial.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
form of cancer in children. ALL of T cell lineage (T-ALL) is
an aggressive malignant disease which accounts for 15 % of
childhood ALL [1]. As opposed to B cell precursor ALL
where cytogenetic abnormalities have been used as stratifying
criteria for several decades, cytogenetic features are not taken
into consideration for therapy in T-ALL.
Analyses of T-ALL have demonstrated various genetic ab-
normalities, some of them detected by conventional cytoge-
netics, whereas others have been more recently detected with
molecular methods [2].Many of the cytogenetic abnormalities
involve the TCR regions, 14q11 (TCR AD) and 7q35 (TCR B).
T(11;14)(p13-15;q11) is the most common translocation iden-
tified in childhood T-ALL; its frequency has been shown to
represent about 7 to 8 % of abnormal karyotypes in childhood
T-ALL large ser ies , wi th a higher frequency of
t(11;14)(p13;q11)/LMO2 compared to t(11;14)(p15;q11)/
LMO1 which is observed in less than 1 % of cases [3–8].
T(11;14)(p13;q11) and t(11;14)(p15;q11) involve the TCRD
gene on 14q11 and the LIM domain only genes, LMO2 or
LMO1 on 11p13 and 11p15 respectively [9]. Both transloca-
tions result in the ectopic expression of LMO2 or LMO1 genes
which are activated by their juxtaposition with promoter/
enhancers of the TCRD gene [10, 11].
The prognostic value of t(11;14) in T-ALL is not clearly
defined. In the series of Ribeiro et al., events occurred in 6/8
patients [6], whereas in the paper of Heerema et al., 13 patients
out of 14 with t(11;14) T-ALL were classified as poor risk
according to NCI criteria [4]. Treatment intensity seems to
play a role in the outcome of patients with t(11;14), but the
low number of t(11;14) patients in each trial has precluded
statistical analysis in most published series so far [4–6]. The
aim of our work was to define the main characteristics of
childhood T-ALL with t(11;14) and to analyze the prognosis
from a series of 20 patients, treated in two consecutive trials
from the European Organization for Research and Treatment
of Cancer Children Leukemia Group (EORTC-CLG) over a
19-year period of time (patients registered from 1989 to 2008).
Patients and methods
Patients and treatment protocol
A cohort of 599 children younger than 18 years with newly
diagnosed T-ALLwere analyzed. All patients were enrolled in
the Children Leukemia Group EORTC 58881 (303 patients)
or 58951 (296 patients) prospective multicentric trials, be-
tween June 1989 and August 2008. Among them, 478 patients
(79.8 %) had a successful G-banding chromosome study at
diagnosis.
Informed consent was provided according to the Declaration
of Helsinki. These protocols have been accepted by the EORTC
Protocol Review Committee and by the ethics committee of
each participating center. Diagnosis of ALL was defined by
the presence of more than 25 % blasts in the bone marrow
aspirate. T cell lineage and T-ALL subclassification were
assessed by immunophenotyping according to the guidelines
of the European Group for the Immunological Characterization
of Leukemias (EGIL) as previously described [12]. Karyotypes
were obtained after short cultures (overnight or 24-h cultures)
and analyzed after G or R banding according to standard pro-
cedures and centrally reviewed and classified according to
ISCN2009 nomenclature. Molecular analyses were performed
according to previously published methods [13].
Complete remission (CR) was defined as less than 5 %
blasts in the bone marrow and normal recovery of normal
hematopoiesis, absence of blasts in peripheral blood, and no
evidence of disease at any other site. The treatment regimen
was adapted from the BFM protocol (Annex 1) and was pre-
viously described [13]. In both studies, patients with T-ALL
were assigned to 2 different risk groups: average risk (IR/
AR2) and very high risk (VHR). The VHR group was defined
by the presence of any of the following criteria: (i) at comple-
tion of the corticosteroid+intrathecal methotrexate prephase
(at day 8), ≥1000 blasts/mm3 in the peripheral blood (so-called
poor prephase Bresponders^ or PPR), and (ii) at completion of
induction, failure to achieve complete remission. In the more
recent 58951 study, an additional VHR feature was minimal
residual disease (MRD) higher or equal to 10−2 (more than
1000 blasts in 100,000 mononuclear marrow cells) at the end
of induction.
Statistical analysis
Event-free survival was calculated from the date of complete
remission to the date of first relapse or death. For patients who
failed to reach complete remission by the end of induction, the
failure was considered as an event at time 0. All patients alive
and in first continuous remission were censored at their last
follow-up. The duration of survival was calculated from the
date of start of diagnosis until the date of death; patients still
alive were censored at their last follow-up. Survival distribu-
tions were estimated according to the Kaplan-Meier tech-
nique, and the standard errors (SE) of the estimates were ob-
tained via the Greenwood formula [14]. The differences be-
tween curves were tested for statistical significance using the
two-tailed log rank test [15]. Baseline characteristics of the
different patient groups were compared by nonparametric tests
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(Fisher’s exact test for qualitative variables, Kruskal-Wallis
test for quantitative variables).
Results
Patients
Among 478 patients with T-ALL and successful karyotype,
a total of 20 patients (4.2 %) with t(11;14) T-ALL were
diagnosed and treated according to the 2 consecutive trials.
Clinical and biological characteristics of those patients are
summarized in Table 1. The median age was 6.4 years (2.6–
16.3 years); there was a male predominance with 18 boys
and only 2 girls. The clinical presentation showed overt
leukemia with mediastinal enlargement in 17 out of 20 and
with extramedullary disease in 7 cases (5 central nervous
system (CNS) involvement, 1 kidney, 1 gonad). At diagno-
sis, the median leukocyte count was 116×109/L, median
hemoglobin level 119 g/L, median platelet count 79×109/
L. The two consecutive groups of patients with t(11;14)
treated in the 58881 trial (9 patients) and in the 58951 trial
(11 patients) did not differ significantly regarding frequency
of mediastinal mass (p=0.83), hemoglobin level (p=0.88),
Table 1 Clinical and laboratory features of T-ALL patients with or without t(11;14)
58881 58951
t(11;14) No Yes No Yes
216 9 242 11
Sex, n (%)
Male 162 (75) 9 (100) 170 (70.2) 9 (81.8)
Female 54 (25) 0 (0) 72 (29.8) 2(18.2)
Age, years
Median 7 5.8 8 9.8
White cell count, ×109/L
Median 75.6 124 45 108.9
<10, n (%) 117 (54.1) 4 (44.4) 165 (68.2) 5 (45.5)
≥10, n (%) 99 (45.9) 5 (55.6) 77 (31.8) 6 (54.5)
Initial blasts, ×109/L
Median 57.7 102.9 60 75.0
Hemoglobin level, g/L
Median 106 118 109 122
Platelet count, ×109/L
Median 79 96 95.5 74
Mediastinal mass, n (%)
Yes 137 (63.4) 7 (77.8) 109 (45) 9 (81.8)
No 78 (36.1) 2 (22.2) 130 (53.7) 2 (18.2)
Missing 1 (0.5) 0 (0) 3 (1.2) 0 (0)
Enlarged liver, n (%)
Yes 160 (74.1) 9 (100) 122 (56.5) 9 (81.8)
No 56 (25.9) 0 (0) 87 (40.3) 2 (18.2)
Missing 0 (0) 0 (0) 7 (3.2) 0 (0)
Enlarged spleen, n (%)
Yes 160 (74.1) 9 (100) 151 (62.4) 9 (81.8)
No 56 (25.9) 0 (0) 83 (34.3) 2 (18.2)
Missing 0 (0) 0 (0) 8 (3.3) 0 (0)
CNS involvement, n (%)
Yes 25 (11.5) 2 (22.2) 31 (12.9) 3 (27.3)
No 184 (85.2) 7 (77.8) 206 (85.1) 8 (72.7)
Missing 7 (3.2) 0 (0) 5 (2) 0 (0)
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white cell count (p=0.97), and platelet count (p=0.64).
There were 2/9 patients with CNS involvement in the
58881 trial and 3/11 patients in the 58951 trial.
Cytogenetics
The t(11;14)(p13;q11) with a 11p13 breakpoint was observed
in most of the karyotypes (18/20) whereas the
t(11;14)(p15;q11) with a 11p15 breakpoint was present in on-
ly 2 patients. The t(11;14) was found either as an isolated
abnormality (7 patients) or was associated to other changes,
but karyotypes were rarely complex. The cytogenetics for the
20 patients are summarized in Table 2.
Immunophenotype and molecular abnormalities
Three patients presented an immature T-ALL, stage I or II
according to EGIL classification. Eleven patients had a more
mature T-ALL corresponding to stage III or IV according to
this classification. The immunophenotype details were incom-
plete for 6 patients with T-ALL.
For 8/20 patients, in whom frozen material was available,
we analyzed the recurrent molecular abnormalities in T-ALL:
Four patients presented a SIL-TAL fusion gene, 3 presented a
NOTCH1 mutation, and no patient presented a HOX11
overexpression.
Therapy
Nine T-ALL patients diagnosed between July 1989 and Sep-
tember 1998 were treated according to the EORTC 58881
trial, and the following 11 patients were treated according to
the EORTC 58951 trial.
Response to the prephase and to induction, MRD
at the end of induction
Concerning the 58881 trial, on day 8, after 7 days of
corticosteroids and one intrathecal injection of metho-
trexate, 6/9 patients were good prephase responders
and were treated according to the increased-risk group
(IR). The 3 patients who responded poorly were then
treated according to the VHR group. Complete remis-
sion was obtained in 89 % of cases (8/9 patients). One
patient never achieved complete remission and died
from refractory disease.
Concerning the more recent protocol, 8/11 patients were
good prephase responders. Seven patients were treated ac-
cording to the AR2 group and 4 according to the VHR group
(one patient with a very high initial white cell count was treat-
ed according to the VHR protocol although he was in the good
prednisone responder group). Complete remission at the end
of induction was obtained in all cases.
Table 2 Cytogenetics
Patients Karyotypes
No. 1 46,XY,der(7)t(7;11)(q35;p11),del(8)(p21),add(9)(p23),t(11;14)(p13;q11)[9]/46,XY[31]
No. 2 46,XY,del(6)(q13q23),t(11;14)(p13;q11)[28]/46,XY[28]
No. 3 46,XY,t(11;14)(p13;q11)[12]
No. 4 46,XY,t(11;14)(p13;q11)[4]
No. 5 46,XY,del(9)(p21),t(11;14)(p13;q11)[20]
No. 6 46,XY,t(11;14)(p13;q11)[5]/46,XY[18]
No. 7 45,XY,del(6)(q21),t(7;17)(p14;p11),-9,t(11;14)(p13;q11)[4]/46,XY[12]
No. 8 47,XY,del(6q),t(11;14)(p13;q11),+21[10]
No. 9 46,XY,t(11;14)(p13;q11)[23]/ 46,XY[34]
No. 10 46,XY,del(9)(p21p22),t(11;14)(p15;q11)[45]/46,XY[6]
No. 11 48,XY,+7,t(11;14)(p13;q11),+?20[25]
No. 12 46,XY,del(9)(p21),t(11;14)(p13;q11)[9]
No. 13 46,XY,t(11;14)(p15;q11)[29]
No. 14 46,XX,t(11;14)(p13;q11)[11]/46,XX[9]
No. 15 46,XY,del(6)(q14q26),t(11;14)(p13;q11)[8]/46,XY[9]
No. 16 46,XY,t(11;14)(p13;q11)[16]/46,XY[19]
No. 17 46,XY,del(9)(p21),t(11;14)(p13;q11),add(18)(q22)[cp9]/46,XY[12]
No. 18 46,XY,del(9)(p13),t(11;14)(p13;q11)[5]/46,XY,idem,dup(17)(q12q25)[5]/46,XY[6]
No. 19 46,XX,t(11;14)(p13;q11)[13]/44,idem,-17,-22[9]
No. 20 46,XY,del(6)(q14q24),del(9)(q23),t(11;14)(p13;q11)[23]/46,XY[5]
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First event after complete remission and value of minimal
residual disease
Among 19 patients who reached complete remission, 9 pa-
tients relapsed (6 in the 58881 trial and 3 in the 58951 trial).
Four patients had isolated bone marrow relapse, 3 patients had
isolated CNS relapse, and 2 patients presented a combined
CNS and bone marrow relapse (and moreover one of these
patients had an associated testicular relapse). Median time
from CR to relapse was 12.4 months with a range of 4.9 to
60.3 months. The patient who presented a late bone marrow
relapse still had a LMO2 rearrangement but with a t(2;11)
translocation and presented the same 6q deletion detected at
diagnosis, thus suggesting a clonal evolution. Patients includ-
ed in the 58881 trial presentedmore relapses or failures than in
the subsequent trial (7 versus 3). Among the 8 patients includ-
ed in the 58951 trial who had an evaluation ofMRD at the end
of induction, 7 had a MRD <10−2; only one experienced a
late relapse (60 months). One poor prednisone-responding
patient had a MRD>10−2 and thus underwent allogenic stem
cell transplantation (SCT) in first CR (see Table 3).
Stem cell transplantation
Five of 20 patients received an allogenic SCT. For 4 of them
included in the 58881 trial, the transplantation was performed
in second complete remission and for 1 included in the more
recent protocol, in first CR with persistent positive minimal
residual disease. One patient received autologous SCT in sec-
ond CR for isolated CNS relapse.
Outcome
We noticed 7 deaths among the 20 patients. Five patients were
included in the 58881 trial and 2 in the 58951 trial. The deaths
were all relapse- or failure-related. Three out of 5 transplanted
children survived. The overall survival rate at 5 years was
65 % with a median follow-up of 6.1 years (range 3.5–
20 years) (Fig. 1a). The overall event-free-survival rate was
47.1 % at 5 years (Fig. 1b). The event-free survival (EFS) rate
was 55.4 % for the intermediate-risk patients whereas patients
treated in the very-high-risk group had an EFS rate of 28.6 %
(p=0.175) (Fig. 2). EFS for patients treated in the 58881 trial
was 22.2 % versus 65.5 % for patients included in the subse-
quent trial 58951 (p=0.015). When analyzing the outcome of
the 20 patients with t(11;14) ALL compared to the other T-
ALLs, in the 58881 study, a presence of t(11;14) was associ-
ated with a poor outcomewith an event-free survival at 5 years
at 22.2 versus 65.1 % (p=0.0004); In contrast, in the more
recent protocol, the outcome of T-ALL with t(11;14) joined
that of non-t(11;14) T-ALL with an event-free survival at
5 years of 65.5 versus 74.9 % (p=0,93) (Fig. 3).
Discussion
Incidence of t(11;14) among T-ALL
In this large series of 478 T-ALL patients with a successful
karyotype, treated in 2 consecutive EORTC Children Leuke-
mia Group trials over 20 years, 20 patients (4.2 %) were di-
agnosed with a translocation t(11;14). This proportion is com-
parable to the 3.9 % (14/354 patients) picture in the main
series published to date [7] and slightly less than the 6.8 %
proportion earlier published by Ribeiro et al. [6]. Other stud-
ies, with less patients, showed the presence of t(11;14) in 5.9
to 21 % of cases [4–7, 16].
Clinical and biological features
Concerning the clinical and biological features, our series of
patients with t(11;14) appears comparable to the ones already
published, with a male predominance, high frequency of me-
diastinal mass (16/20, 80 %), and high leukocyte counts [4, 6,
7]. Concerning immunophenotype, in our series, all
Table 3 Outcome results according to the two consecutive protocols
58881 58951
Response to the prephase
Good responders 6 8
Bad responders 3 3
Achievement of complete remission
Yes 9 11
No 1 0
MRD value after induction
<10−2 0 7
≥10−2 0 1
Missing or inevaluable 9 3
Relapse or initial failure
Yes 7 3
No 2 8
Site of relapse
Isolated bone marrow 2 2
Combined bone marrow 1 1
Isolated CNS 3 0
Stem cell transplantation
Yes 4 1
No 1 10
Survival status
Death 5 2
Alive 4 9
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maturation stages could be associated with a T-ALL with
t(11;14), albeit some authors published an association be-
tween t (11;14) and in te rmedia te -T or mature-T
immunophenotype [6, 17]. A study published in 1997 sug-
gested that T-ALL with pro-T immunophenotype (CD7+,
CD2−, CD5−) is a subgroup presenting a poor prognosis
[18]. More recently, it was published that T-ALL with early
T cell precursor (CD1a−, CD8−, CD5 weak with stem cell or
myeloid markers) also fared poorly [19]. There were no pa-
tients with a t(11;14) in this study, thus suggesting that the
t(11;14) chromosomal event occurs at a later stage of T cell
differentiation.
Molecular abnormalities
In our series, 3/6 analyzable patients had a Notchmutation and
4/10 presented a positive SIL-TAL fusion. This proportion is
comparable to that described in large series of T-ALL [20, 21].
No patient exhibited HOX11 overexpression that has been
described as a favorable feature in T-ALL [21–23]. No patient
with t(11;14) and NOTCH1 mutation relapsed; nevertheless,
the small number of patients in this study does not enable us to
conclude about the prognostic significance of molecular ab-
normalities in t(11;14) T-ALL. Although several recurrent ge-
netic alterations have been identified in T cell leukemias, it is
noteworthy that, in contrast to B-ALL, none of them have
been so far used to stratify the therapy in childhood T-ALL.
Impact of therapeutic trial
Event-free survival of 65 and 75 % obtained in non-t(11;14)
patients treated in the two consecutive EORTC 58881 (1990–
1998) and 58951 (1999–2008) trials is close to the results of T-
ALL in other groups in the same period. For instance, the
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Fig. 3 Event-free survival of T-
ALL with t(11;14) or not. a
EORTC trial 58881, b EORTC
trial 58951
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DFCI Consortium describes a 5-year EFS of 78.6 % in the 91-
01 study (1991–1996) and 84.6 % in the 95-01 study (1996–
2000) [24].
The 2 groups of children treated in the 2 EORTC consec-
utive trials were similar: The presentation at diagnosis and the
proportion of very-high-risk patients did not differ, but we
noticed a difference concerning the outcome: 7/9 patients
failed to achieve remission or relapsed in the first protocol
while only 3/10 patients relapsed in the more recent trial. This
difference in outcome is not explained by initial risk group
features since the proportion of PPR patients is comparable in
both cohorts (3 VHR patients in 58881 and 2 in 58951). The
VHR criteria are similar in the 2 consecutive protocols (poor
prednisolone response, no complete remission after induc-
tion). We can hypothesize that the main progresses were
achieved in patients without VHR features: in trial 58951,
no patient out of 7 treated according to average-risk group 2
relapsed, compared with 4/7 failures in patients in trial 58851.
These data have to be considered cautiously in view of the
small number of t(11;14) T-ALL compared to the other T-
ALL.
Cumulative doses of chemotherapy of the 2 trials are de-
scribed (Table 4). A higher dose of asparaginase (530,000 ver-
sus 30,000 IU/m2) has been shown to be effective in reducing
T-ALL relapse rate in the POG 8704 study [25]. A less effec-
tive antileukemic activity of Erwinia given at 10,000 IU/m2
twice weekly was reported in the 58881 trial but only one
patient in this series received Erwinia instead of E. coli
asparaginase and relapsed, which may not explain solely the
worse results observed in the late trial [26]. A trial is currently
conducted by the AEIOP-BFM group to investigate whether
further improvements can be obtained using PEG-asparaginase
instead of native asparaginase in T-ALL (AEIOP-BFM 2009).
Doses and types of glucocorticoids were also different in
the 2 trials (Table 4). Although essential in the treatment of
ALL, the ideal dose of glucocorticoids in T-ALL is still under
debate [27]. There were 3 isolated CNS relapses in the first
trial, compared to one in the more recent protocol in which
half of the patients were randomized to receive dexametha-
sone instead of prednisolone in induction and late reinduction.
Out of 5 patients treated with dexamethasone 6 mg/m2/day in
induction, 2 relapsed; by comparison 8/15 patients who re-
ceived prednisolone 60 mg/m2/day in induction presented a
relapse. It is known that, even if dexamethasone and prednis-
olone during induction might have equal efficacy, dexameth-
asone decreases the CNS relapse incidence rate [28, 29].
Moreover dexamethasone at 10mg/m2/day appears statistical-
ly superior to prednisone at 60 mg/m2/day in ALL of T-
lineage [30]. Although a series published in 2005 did not find
a superiority of dexamethasone over prednisolone regarding
EFS, no patient presented with high-risk criteria or CNS in-
volvement in this patient group [31]. It has been shown that
HD-MTX, associated with intrathecal injections, prevents
CNS and systemic relapses [32]. For example, in a random-
ized study of childhood ALL published in 2011, EFS rate was
79.5 % in the group containing HD-MTX therapy versus
Table 4 Cumulative dose of chemotherapy according to treatment protocols
58881 IR 58951 IR 58881 VHR 58951 VHR
Prednisolone 1680 mg/m2 1680 or 0 mg/m2
according to randomization
1680 mg/m2 1680 or 0 mg/m2
according to randomization
Dexamethasone 210 mg/m2 126 or 294 mg/m2
according to randomization
700 mg/m2 900 or 1068 mg/m2
according to randomization
Vincristine 12 mg/m2 12 mg/m2 12 mg/m2 15 mg/m2
Daunorubicine 120 mg/m2 120 mg/m2 220 mg/m2 270 mg/m2
Methotrexatea 20 g/m2 25 g/m2 50 g/m2 50 g/m2
Asparaginase 120,000 ui/m2 180,000 or 240,000 ui/m2
according to randomization
420,000 ui/m2 3,300,000 ui/m2
Cyclophosphamide 3 g/m2 4 g/m2 2 g/m2 3 g/m2
Cytarabine 1800 or 9800 mg/m2
according to randomization
1800 mg/m2 36 g/m2 36 g/m2
6-Mercaptopurinea 3080 mg/m2 3080 mg/m2 3100 mg/m2 2550 mg/m2
Doxorubicine 120 mg/m2 120 mg/m2
6-Thioguanine 840 mg/m2 840 mg/m2 1000 mg/m2 1500 mg/m2
Mitoxantrone 16 mg/m2 16 mg/m2
Etoposide 1350 mg/m2 1350 mg/m2
Vindesine 6 mg/m2 9 mg/m2
IR intermediate risk, VHR very high risk
a Not taking into consideration maintenance therapy
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67.5 % (p=0.047) [33]. In our two consecutive trials, the
number of intrathecal injections evolved from 9 in 58881 to
16 in 58951 and the amount of HD-MTX evolved from 20 to
25 g in the intermediate-risk group. While maintenance ther-
apy was different according to the protocols and was more
intensive in the 58951 trial (6 additional intrathecal injections
for non VHR patients and 5 for VHR patients), the impact of
maintenance therapy is probably of less importance since the
median time to relapse was 10.7 months in this series of pa-
tients. In our series, all relapses of t(11;14) T-ALL except one
occurred early as usual for T cell ALL. However, in one pa-
tient with late bone marrow relapse (60.3 months), the cyto-
genetic data suggested a major clonal evolution or possibly a
second event affecting again the LMO2 locus. This phenom-
enon is not rare among patients with T-ALL [34].
The level of MRD after induction is of utmost importance
in childhood ALL [35], as highlighted in our series where only
1/8 patients with low MRD level post induction relapsed.
However, it has recently been showed that the value of
MRD after BFM-based consolidation is more discriminant
for the outcome in T cell ALL [36]. Five patients received
allogenic SCT, performed in second complete remission for
4 of them. Three out of 5 transplanted patients survived.
Therefore, stem cell transplantation can be considered a cura-
tive procedure in relapsed patients with T-ALL t(11;14). One
study published in 2006 tends to demonstrate that stem cell
transplantation is superior to chemotherapy alone for children
with high-risk T-ALL [37]. For this reason, study of minimal
residual disease after induction is of major importance to de-
termine which patients will benefit from allogenic HSCT.
Conclusion
Our study describes a series of T-ALL patients with t(11;14)
treated in 2 consecutive trials EORTC 58881 and EORTC
58951. The presence of t(11;14) appeared as a poor prognostic
feature in the 58881 trial, whereas this abnormality no longer
affected the outcome, as compared to other T-ALL in the more
recent 58951 trial. This might be explained by the higher
treatment intensity in the latter trial. HSCT can be curative
for relapsed patients who reached a second CR and for pa-
tients with high-risk features. These data tend to indicate that
t(11;14) T-ALL does not anymore appear as a disease of worse
prognosis than other T-ALLs under the condition that it is
treated intensively.
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